» Articles » PMID: 37865975

SPI1 Activates TGF-β1/PI3K/Akt Signaling Through Transcriptional Upregulation of FKBP12 to Support the Mesenchymal Phenotype of Glioma Stem Cells

Overview
Journal Brain Pathol
Date 2023 Oct 22
PMID 37865975
Authors
Affiliations
Soon will be listed here.
Abstract

Glioma stem cells (GSCs) exhibit diverse molecular subtypes with the mesenchymal (MES) population representing the most malignant variant. The oncogenic potential of Salmonella pathogenicity island 1 (SPI1), an oncogenic transcription factor, has been established across various human malignancies. In this study, we explored the association between the SPI1 pathway and the MES GSC phenotype. Through comprehensive analysis of the Cancer Genome Atlas and Chinese Glioma Genome Atlas glioma databases, along with patient-derived GSC cultures, we analyzed SPI1 expression. Using genetic knockdown and overexpression techniques, we assessed the functional impact of SPI1 on GSC MES marker expression, invasion, proliferation, self-renewal, and sensitivity to radiation in vitro, as well as its influence on tumor formation in vivo. Additionally, we investigated the downstream signaling cascades activated by SPI1. Our findings revealed a positive correlation between elevated SPI1 expression and the MES phenotype, which in turn, correlated with poor survival. SPI1 enhanced GSC MES differentiation, self-renewal, and radioresistance in vitro, promoting tumorigenicity in vivo. Mechanistically, SPI1 augmented the transcriptional activity of both TGF-β1 and FKBP12 while activating the non-canonical PI3K/Akt pathway. Notably, inhibition of TGF-β1/PI3K/Akt signaling partially attenuated SPI1-induced GSC MES differentiation and its associated malignant phenotype. Collectively, our results underscore SPI1's role in activating TGF-β1/PI3K/Akt signaling through transcriptional upregulation of FKBP12, thereby supporting the aggressive MES phenotype of GSCs. Therefore, SPI1 emerges as a potential therapeutic target in glioma treatment.

Citing Articles

Brain gliomas new transcriptomic discoveries from differentially expressed genes to therapeutic targets.

Pei S, Jiang Z, Cheng H Sci Rep. 2025; 15(1):2553.

PMID: 39833228 PMC: 11746978. DOI: 10.1038/s41598-025-86316-0.


Construction of a Prognostic Model for Mitochondria and Macrophage Polarization Correlation in Glioma Based on Single-Cell and Transcriptome Sequencing.

Chen P, Wang H, Zhang Y, Qu S, Zhang Y, Yang Y CNS Neurosci Ther. 2024; 30(11):e70083.

PMID: 39491527 PMC: 11532235. DOI: 10.1111/cns.70083.


SPI1 activates TGF-β1/PI3K/Akt signaling through transcriptional upregulation of FKBP12 to support the mesenchymal phenotype of glioma stem cells.

Song Y, Zhang Y, Wang X, Han X, Shi M, Xu L Brain Pathol. 2023; 34(3):e13217.

PMID: 37865975 PMC: 11007049. DOI: 10.1111/bpa.13217.

References
1.
Hu Y, Smyth G . ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009; 347(1-2):70-8. DOI: 10.1016/j.jim.2009.06.008. View

2.
Behnan J, Finocchiaro G, Hanna G . The landscape of the mesenchymal signature in brain tumours. Brain. 2019; 142(4):847-866. PMC: 6485274. DOI: 10.1093/brain/awz044. View

3.
Wang T, Li B, Danielson P, Shah P, Rockwell S, Lechleider R . The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell. 1996; 86(3):435-44. DOI: 10.1016/s0092-8674(00)80116-6. View

4.
Rimmele P, Komatsu J, Hupe P, Roulin C, Barillot E, Dutreix M . Spi-1/PU.1 oncogene accelerates DNA replication fork elongation and promotes genetic instability in the absence of DNA breakage. Cancer Res. 2010; 70(17):6757-66. DOI: 10.1158/0008-5472.CAN-09-4691. View

5.
Gao J, Dai C, Yu X, Yin X, Zhou F . Long noncoding RNA LINC00324 exerts protumorigenic effects on liver cancer stem cells by upregulating fas ligand via PU box binding protein. FASEB J. 2020; 34(4):5800-5817. DOI: 10.1096/fj.201902705RR. View